What is the typical dosing regimen for hydralazine (direct vasodilator) in patients with hypertension or heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hydralazine Dosing Regimens for Hypertension and Heart Failure

For hypertension, start hydralazine at 10 mg four times daily for the first 2-4 days, increase to 25 mg four times daily for the remainder of the first week, then increase to 50 mg four times daily for maintenance, with dosage adjustments to the lowest effective level. 1

Dosing for Hypertension

  • Initial therapy should begin with 10 mg four times daily for the first 2-4 days, then increase to 25 mg four times daily for the remainder of the first week 1
  • For the second week and beyond, increase dosage to 50 mg four times daily 1
  • Maintenance dosage should be adjusted to the lowest effective level to minimize adverse effects 1
  • For resistant hypertension, doses up to 300 mg daily may be required, though this increases risk of adverse effects including drug-induced lupus-like syndrome 1
  • When higher doses are needed, consider combining hydralazine with a thiazide diuretic, reserpine, or a beta-blocker to allow for lower hydralazine doses 1, 2

Dosing for Heart Failure

  • For heart failure with reduced ejection fraction (HFrEF), hydralazine is typically used in combination with isosorbide dinitrate 3
  • The initial dose in the fixed-dose combination is 37.5 mg hydralazine/20 mg isosorbide dinitrate three times daily 3
  • This can be increased to 75 mg hydralazine/40 mg isosorbide dinitrate three times daily as needed and tolerated 3
  • This combination is particularly beneficial in African American patients with HFrEF who remain symptomatic despite standard therapy 3
  • In severe refractory heart failure, doses of 75-100 mg have shown hemodynamic improvements, with 100 mg producing substantial increases in cardiac index and decreases in systemic vascular resistance 4

Special Considerations

  • Acetylator status affects dosing requirements - fast acetylators may require approximately twice the dose compared to slow acetylators 5
  • In patients with impaired renal function (creatinine clearance <35 ml/min), the duration of action is significantly prolonged (14.3 hours vs 7.9 hours), requiring dose adjustment and extended intervals 4
  • Blood pressure should be closely monitored after initiation and during dose titration 3
  • Hydralazine is not recommended as a first-line agent for hypertension but rather as a secondary agent 6

Adverse Effects and Monitoring

  • Common adverse effects include headache, dizziness, and gastrointestinal complaints 3
  • Hydralazine can cause sodium and water retention, reflex tachycardia, and at higher doses may induce a lupus-like syndrome 6, 1
  • When using hydralazine without beta-blockers, significant increases in heart rate may occur (up to 12.4 beats/min) 2
  • Combination with beta-blockers (like propranolol) can mitigate the reflex tachycardia associated with hydralazine therapy 2

Administration Timing

  • For hypertension, conventional hydralazine is typically administered 2-4 times daily 1, 7
  • Slow-release formulations may allow for once-daily dosing in some patients 7
  • Standard formulations given once daily may provide inadequate 24-hour coverage, particularly in rapid acetylators 7

Remember that hydralazine dosing often requires individualization based on clinical response and monitoring of blood pressure, particularly in heart failure patients where hemodynamic effects can vary significantly between individuals 4.

References

Guideline

Hydralazine Dosing Regimens for Hypertension and Heart Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Hemodynamic evaluation of hydralazine dosage in refractory heart failure.

Clinical pharmacology and therapeutics, 1980

Research

Hydralazine dose-response curve analysis.

Journal of pharmacokinetics and biopharmaceutics, 1990

Guideline

Management of Hypotension with Low Diastolic Blood Pressure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Hydralazine once daily in hypertension.

British medical journal (Clinical research ed.), 1982

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.